Treatment Preferences of Physicians Treating Adult Patients with Attention-Deficit/Hyperactivity Disorder in the United States and Canada: A Discrete Choice Experiment
Abstract Introduction Factors influencing attention-deficit/hyperactivity disorder (ADHD) treatment preferences have been studied among patients but not physicians in the United States (US) and Canada. This study assessed treatment preferences of physicians treating adult patients with ADHD in both...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2024-11-01
|
| Series: | Neurology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40120-024-00681-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585279872958464 |
|---|---|
| author | Jeff Schein Martin Cloutier Marjolaine Gauthier-Loiselle Maryaline Catillon Yan Meng Beatrice Libchaber Fanny Jiang Ann Childress |
| author_facet | Jeff Schein Martin Cloutier Marjolaine Gauthier-Loiselle Maryaline Catillon Yan Meng Beatrice Libchaber Fanny Jiang Ann Childress |
| author_sort | Jeff Schein |
| collection | DOAJ |
| description | Abstract Introduction Factors influencing attention-deficit/hyperactivity disorder (ADHD) treatment preferences have been studied among patients but not physicians in the United States (US) and Canada. This study assessed treatment preferences of physicians treating adult patients with ADHD in both countries. Methods An online discrete choice experiment (DCE) was conducted (October 4–20, 2023) among physicians from Dynata’s US and Canadian panel who treated adult patients with ADHD. Preference weights for efficacy (improvement in ADHD symptoms) and safety [risks of adverse events (AEs)] attributes were estimated using a conditional logistic regression model, and were used to calculate the willingness to trade-off and relative importance of the attributes. Results Among 510 US and 347 Canadian physicians (64.1% and 69.2% male, respectively), improvement in ADHD symptoms had a significant positive impact, and the risks of AEs (except the risk of feeling jittery in Canada) had a significant negative impact on physician preferences for ADHD treatments. US physicians were willing to tradeoff 0.44, 0.35, 0.20, 0.17, and 0.17 percentage points of improvement in ADHD symptoms to avoid a one-percentage-point risk of insomnia, nausea, feeling jittery, anxiety, and dry mouth, respectively; among Canadian physicians, these were 0.31, 0.21, 0.12, 0.20, and 0.07, respectively. The relative importance of the efficacy versus safety attributes (i.e., the risks of AEs included in the DCE taken together) was 45.5% versus 54.5% in the US and 56.3% versus 43.7% in Canada. Conclusion Efficacy was the most important single attribute for physicians treating adult patients with ADHD in both the US and Canada; however, the risks of AEs taken together had greater relative importance than efficacy alone among US but not Canadian physicians. These findings highlight potential discrepancies in physician and patient preferences based on existing evidence and underscore the importance of shared decision-making, which may in turn increase patients’ treatment satisfaction. |
| format | Article |
| id | doaj-art-53aead19171f446a956c45ab828e43d2 |
| institution | Kabale University |
| issn | 2193-8253 2193-6536 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Neurology and Therapy |
| spelling | doaj-art-53aead19171f446a956c45ab828e43d22025-01-26T12:58:38ZengAdis, Springer HealthcareNeurology and Therapy2193-82532193-65362024-11-0114119321010.1007/s40120-024-00681-yTreatment Preferences of Physicians Treating Adult Patients with Attention-Deficit/Hyperactivity Disorder in the United States and Canada: A Discrete Choice ExperimentJeff Schein0Martin Cloutier1Marjolaine Gauthier-Loiselle2Maryaline Catillon3Yan Meng4Beatrice Libchaber5Fanny Jiang6Ann Childress7Otsuka Pharmaceutical Development and Commercialization, Inc.Analysis Group, Inc.Analysis Group, Inc.Analysis Group, Inc.Analysis Group, Inc.Analysis Group, Inc.Analysis Group, Inc.Center for Psychiatry and Behavioral MedicineAbstract Introduction Factors influencing attention-deficit/hyperactivity disorder (ADHD) treatment preferences have been studied among patients but not physicians in the United States (US) and Canada. This study assessed treatment preferences of physicians treating adult patients with ADHD in both countries. Methods An online discrete choice experiment (DCE) was conducted (October 4–20, 2023) among physicians from Dynata’s US and Canadian panel who treated adult patients with ADHD. Preference weights for efficacy (improvement in ADHD symptoms) and safety [risks of adverse events (AEs)] attributes were estimated using a conditional logistic regression model, and were used to calculate the willingness to trade-off and relative importance of the attributes. Results Among 510 US and 347 Canadian physicians (64.1% and 69.2% male, respectively), improvement in ADHD symptoms had a significant positive impact, and the risks of AEs (except the risk of feeling jittery in Canada) had a significant negative impact on physician preferences for ADHD treatments. US physicians were willing to tradeoff 0.44, 0.35, 0.20, 0.17, and 0.17 percentage points of improvement in ADHD symptoms to avoid a one-percentage-point risk of insomnia, nausea, feeling jittery, anxiety, and dry mouth, respectively; among Canadian physicians, these were 0.31, 0.21, 0.12, 0.20, and 0.07, respectively. The relative importance of the efficacy versus safety attributes (i.e., the risks of AEs included in the DCE taken together) was 45.5% versus 54.5% in the US and 56.3% versus 43.7% in Canada. Conclusion Efficacy was the most important single attribute for physicians treating adult patients with ADHD in both the US and Canada; however, the risks of AEs taken together had greater relative importance than efficacy alone among US but not Canadian physicians. These findings highlight potential discrepancies in physician and patient preferences based on existing evidence and underscore the importance of shared decision-making, which may in turn increase patients’ treatment satisfaction.https://doi.org/10.1007/s40120-024-00681-yAtomoxetineAttention-deficit/hyperactivity disorderCentanafadineDecision-makingDiscrete choice experimentLisdexamfetamine |
| spellingShingle | Jeff Schein Martin Cloutier Marjolaine Gauthier-Loiselle Maryaline Catillon Yan Meng Beatrice Libchaber Fanny Jiang Ann Childress Treatment Preferences of Physicians Treating Adult Patients with Attention-Deficit/Hyperactivity Disorder in the United States and Canada: A Discrete Choice Experiment Neurology and Therapy Atomoxetine Attention-deficit/hyperactivity disorder Centanafadine Decision-making Discrete choice experiment Lisdexamfetamine |
| title | Treatment Preferences of Physicians Treating Adult Patients with Attention-Deficit/Hyperactivity Disorder in the United States and Canada: A Discrete Choice Experiment |
| title_full | Treatment Preferences of Physicians Treating Adult Patients with Attention-Deficit/Hyperactivity Disorder in the United States and Canada: A Discrete Choice Experiment |
| title_fullStr | Treatment Preferences of Physicians Treating Adult Patients with Attention-Deficit/Hyperactivity Disorder in the United States and Canada: A Discrete Choice Experiment |
| title_full_unstemmed | Treatment Preferences of Physicians Treating Adult Patients with Attention-Deficit/Hyperactivity Disorder in the United States and Canada: A Discrete Choice Experiment |
| title_short | Treatment Preferences of Physicians Treating Adult Patients with Attention-Deficit/Hyperactivity Disorder in the United States and Canada: A Discrete Choice Experiment |
| title_sort | treatment preferences of physicians treating adult patients with attention deficit hyperactivity disorder in the united states and canada a discrete choice experiment |
| topic | Atomoxetine Attention-deficit/hyperactivity disorder Centanafadine Decision-making Discrete choice experiment Lisdexamfetamine |
| url | https://doi.org/10.1007/s40120-024-00681-y |
| work_keys_str_mv | AT jeffschein treatmentpreferencesofphysicianstreatingadultpatientswithattentiondeficithyperactivitydisorderintheunitedstatesandcanadaadiscretechoiceexperiment AT martincloutier treatmentpreferencesofphysicianstreatingadultpatientswithattentiondeficithyperactivitydisorderintheunitedstatesandcanadaadiscretechoiceexperiment AT marjolainegauthierloiselle treatmentpreferencesofphysicianstreatingadultpatientswithattentiondeficithyperactivitydisorderintheunitedstatesandcanadaadiscretechoiceexperiment AT maryalinecatillon treatmentpreferencesofphysicianstreatingadultpatientswithattentiondeficithyperactivitydisorderintheunitedstatesandcanadaadiscretechoiceexperiment AT yanmeng treatmentpreferencesofphysicianstreatingadultpatientswithattentiondeficithyperactivitydisorderintheunitedstatesandcanadaadiscretechoiceexperiment AT beatricelibchaber treatmentpreferencesofphysicianstreatingadultpatientswithattentiondeficithyperactivitydisorderintheunitedstatesandcanadaadiscretechoiceexperiment AT fannyjiang treatmentpreferencesofphysicianstreatingadultpatientswithattentiondeficithyperactivitydisorderintheunitedstatesandcanadaadiscretechoiceexperiment AT annchildress treatmentpreferencesofphysicianstreatingadultpatientswithattentiondeficithyperactivitydisorderintheunitedstatesandcanadaadiscretechoiceexperiment |